The purpose of this study is to evaluate the development of anti-drug antibody to biosimilar
      CT-P13 and to assess the change of drug concentration for 1 year in patients with moderately
      to severe inflammatory bowel disease.

Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease

Inflammatory Bowel Disease

Ulcerative Colitis

Crohn's Disease

Occurrence of Anti-drug Antibody and Change of Drug Level for 1 Year After CT-P13 Therapy and Their Impact on Clinical Outcomes in Moderate to Severe Inflammatory Bowel Disease (OACIS Study)

Professor

Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13

Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13

Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease

About this trial

Study ID

Status

Type

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?